Thread by @KrutikaKuppalli

Interesting info from Wuhan. From 2/4/20-2/28/20 62 pts with #COVID19 randomized to receive SOC vs SOC+HCQ medrxiv.org/content/10.110…

1. Inclusion:
- >18
- RT-PCR positive #SARSCoV2
- Chest CT w/ PNA
- SaO2/SPO2 ratio >93% or P/F ratio >300
- Willing to be randomized

2. Exclusion:
- Severe/critical illness not deemed to meet benefit
- Retinopathy/Retinal dz
- Conduction block or arrhythmia
- Liver Dz (Child-Pugh >C or AST >2x ULN)
-Pregnant/Breastfeeding
-GFR <30 or CRRT
-Received other tx for COVID w/in 30d
-Transfer to OSH in 72h

3. Patients:
- 62 patients randomized to SOC vs SOC + HCQ 200 mg bid x 5 d
4. Endpoints:
- Time to clinical recovery (TTCR) normalization of temp and cough relief
- Change in CT lung findings

4. Results:
- 62 enrolled, mean age 44.7
- 46.8% male and 53.2% female
5. TTCR
- 17 in control and 22 in HCQ had fever at day 0
- Body temp recovery time shortened in HCQ group (2.2 vs 3.2 d)

-15 in control and 22 in HCQ had cough at day 0
- Cough recovery faster in HCQ (2.0 vs 3.1 d)
- 4/62 developed severe illness (all in control)
6. Pneumonia
80.6% in HCQ group with improvement at day 6 imaging
54.8% in control with improvement at day 6 imaging

What does this mean
- Possibly that HCQ may have some effect on improvement of sx and radiographic findings vs SOC, however many limitations

Limitations
- Very small study
- Not powered for efficacy
- Do not know about other co-morbid differences between patients

Limitations (continued)
- Although clinical improvement would want virological information as well
- Numerous exclusion criteria to be involved
- Want more information about SOC arm to understand confounders